Status: Point in time view as at 31/12/2020. Changes to legislation: There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 145. (See end of Document for details)

# $S\,C\,H\,E\,D\,U\,L\,E\,S$

#### SCHEDULE 2

Amendment of the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

## PART 11

Amendment of Part 12 (amendment of Part 12 (dealings with medicinal products))

**145.** For regulation 191 (amendment of regulation 233 (exemption for supply etc under a PGD by a person conducting a retail pharmacy business)) substitute—

"191. For regulation 233(7) substitute—

"(7) Condition F is that when the prescription only medicine is supplied or (as the case may be) administered—

- (a) in Northern Ireland, a UKMA(NI), UKMA(UK), EU marketing authorisation, Article 126a authorisation, certificate of registration, THR(NI) or THR(UK), or
- (b) in Great Britain, a UKMA(GB), UKMA(UK), certificate of registration, THR(GB) or THR(UK),

is in force in relation to it.".".

#### **Commencement Information**

II Sch. 2 para. 145 in force at 31.12.2020 immediately before IP completion day, see reg. 1

### Status:

Point in time view as at 31/12/2020.

### Changes to legislation:

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 145.